Big pharma, M&A

In a M&A deal, Gilead Sciences acquired YM Biosciences for $510 million

Posted on 14 December 2012

Tags: , ,

Gilead Sciences and YM BioSciences have signed a definitive m&a agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash.

Under the terms of this m&a agreement, upon closing of the proposed transaction, shareholders of YM will receive U.S.$2.95 per common share in cash. Others including holders of warrants and stock options will receive a cash payment equal to the difference between U.S.$2.95 and the exercise price of such warrant or stock option.

Gilead plans to fund this m&a with cash on hand.

YM’s lead drug candidate, CYT387, is an orally-administered, once-daily, selective inhibitor of the Janus kinase family, specifically JAK1 and JAK2.

The JAK enzymes have been implicated in a number of disorders including myeloproliferative diseases, inflammatory disorders and certain cancers.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary

Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies

Report: Practical Guide to Finding Partners

Report: Partnering Deals and Alliances with Big Pharma

Report: Partnering Deals and Alliances with Gilead Sciences

Related reports: Merger and Acquisition Terms and Agreements

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply